GVT
BMRN icon

Genesee Valley Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Genesee Valley Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,029
Closed -$213K – 235
2015
Q4 		$213K Buy
2,029
+23
+1% +$2.4K 0.14% 211
2015
Q3 		$211K Sell
2,006
-22
-1% -$2.94K 0.14% 213
2015
Q2 		$277K Buy
2,028
+237
+13% +$29.4K 0.18% 197
2015
Q1 		$223K Buy
+1,791
New +$190K 0.14% 240

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Genesee Valley Trust's BMRN Position: Q1 2016 in Review

Genesee Valley Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 2,029 shares — an estimated $213K sold.

Genesee Valley Trust first reported a position in BMRN in Q1 2015 and held it in 4 quarters. The position peaked at $277K in Q2 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

  • Genesee Valley Trust reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Genesee Valley Trust sold 2,029 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $213K.
  • Genesee Valley Trust first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Genesee Valley Trust's BioMarin Pharmaceuticals position peaked at $277K in Q2 2015.
  • 390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Genesee Valley Trust's 13F filing for Q1 2016, filed 11 May 2016.